Sangamo Therapeutics Valuation
| SGMO Stock | USD 1.96 0.01 0.51% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Sangamo Therapeutics has a current Real Value of $3.07 per share. The regular price of the company is $1.96. Our model measures the value of Sangamo Therapeutics from inspecting the company fundamentals such as Return On Equity of -1.94, current valuation of 397.47 M, and Shares Owned By Insiders of 2.38 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Sangamo Therapeutics' valuation include:
Price Book 10.4499 | Enterprise Value 397.5 M | Enterprise Value Ebitda (1.00) | Price Sales 7.7807 | Enterprise Value Revenue 7.6012 |
Undervalued
Today
Please note that Sangamo Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Sangamo Therapeutics is based on 3 months time horizon. Increasing Sangamo Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sangamo Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sangamo Stock. However, Sangamo Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.96 | Real 3.07 | Target 6.58 | Hype 1.64 | Naive 1.24 |
The intrinsic value of Sangamo Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sangamo Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sangamo Therapeutics helps investors to forecast how Sangamo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sangamo Therapeutics more accurately as focusing exclusively on Sangamo Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Sangamo Therapeutics' intrinsic value based on its ongoing forecasts of Sangamo Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Sangamo Therapeutics' closest peers.
Sangamo Therapeutics Cash |
|
Sangamo Valuation Trend
Knowing Sangamo Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Sangamo Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Sangamo Therapeutics Total Value Analysis
Sangamo Therapeutics is at this time expected to have valuation of 397.47 M with market capitalization of 563.24 M, debt of 38.1 M, and cash on hands of 315.72 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Sangamo Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
397.47 M | 563.24 M | 38.1 M | 315.72 M |
Sangamo Therapeutics Investor Information
About 39.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.24. Sangamo Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Sangamo Therapeutics' liquidity, profitability, solvency, and operating efficiency, Sangamo Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Sangamo Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sangamo Therapeutics has an asset utilization ratio of 106.6 percent. This suggests that the Company is making $1.07 for each dollar of assets. An increasing asset utilization means that Sangamo Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Sangamo Therapeutics Ownership Allocation
Sangamo Therapeutics shows a total of 208.22 Million outstanding shares. 30% of Sangamo Therapeutics outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sangamo Therapeutics Profitability Analysis
The company reported the previous year's revenue of 176.23 M. Net Loss for the year was (257.83 M) with loss before overhead, payroll, taxes, and interest of (138.6 M).About Sangamo Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Sangamo Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Sangamo Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Sangamo Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Sangamo Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Sangamo Therapeutics. We calculate exposure to Sangamo Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sangamo Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -45.3 M | -43.1 M | |
| Pretax Profit Margin | (1.49) | (1.57) | |
| Operating Profit Margin | (1.55) | (1.63) | |
| Net Loss | (1.46) | (1.54) | |
| Gross Profit Margin | (0.26) | (0.24) |
Sangamo Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 174.4 M |
Sangamo Therapeutics Current Valuation Indicators
Sangamo Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Sangamo Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Sangamo Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Sangamo Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Sangamo Therapeutics' worth.When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share 0.066 | Quarterly Revenue Growth (0.95) | Return On Assets (0.58) | Return On Equity (1.94) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.